Par Drugs [PAR] vs Bal Pharma [BALPHARMA] Detailed Comparison
Par Drugs
Bal Pharma
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Par Drugs wins in 13 metrics, Bal Pharma wins in 5 metrics, with 0 ties. Par Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Par Drugs | Bal Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 10.55 | 21.86 | Par Drugs |
| Price-to-Book Ratio | 1.43 | 2.53 | Par Drugs |
| Debt-to-Equity Ratio | 0.00 | 196.55 | Par Drugs |
| PEG Ratio | N/A | -2.84 | N/A |
| EV/EBITDA | 5.98 | 11.31 | Par Drugs |
| Profit Margin (TTM) | 13.23% | 2.38% | Par Drugs |
| Operating Margin (TTM) | 6.75% | 6.67% | Par Drugs |
| EBITDA Margin (TTM) | 6.75% | 6.67% | Par Drugs |
| Return on Equity | 14.47% | 9.87% | Par Drugs |
| Return on Assets (TTM) | 8.97% | 3.78% | Par Drugs |
| Free Cash Flow (TTM) | $149.34M | $15.28M | Par Drugs |
| Dividend Yield | N/A | 1.20% | N/A |
| 1-Year Return | -56.21% | -16.15% | Bal Pharma |
| Price-to-Sales Ratio (TTM) | 1.40 | 0.54 | Bal Pharma |
| Enterprise Value | $1.17B | $3.34B | Bal Pharma |
| EV/Revenue Ratio | 1.16 | 1.10 | Bal Pharma |
| Gross Profit Margin (TTM) | 56.21% | 46.29% | Par Drugs |
| Revenue per Share (TTM) | $82 | $192 | Bal Pharma |
| Earnings per Share (Diluted) | $10.87 | $4.52 | Par Drugs |
| Beta (Stock Volatility) | -0.39 | 0.20 | Par Drugs |
Par Drugs vs Bal Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Par Drugs | -2.00% | 3.75% | 13.73% | 7.52% | -43.87% | -46.83% |
| Bal Pharma | -0.91% | -2.67% | -2.36% | -8.91% | -11.06% | -22.42% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Par Drugs | -56.21% | -39.18% | 349.71% | 122.59% | 122.59% | 122.59% |
| Bal Pharma | -16.15% | -0.19% | 129.28% | 24.90% | 240.35% | 69.15% |
Performance & Financial Health Analysis: Par Drugs vs Bal Pharma
| Metric | PAR | BALPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.41B | ₹1.65B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 13,775 | 11,780 |
| 90 Day Avg. Volume | 8,786 | 16,006 |
| Last Close | ₹110.18 | ₹97.59 |
| 52 Week Range | ₹81.01 - ₹348.45 | ₹78.06 - ₹157.98 |
| % from 52W High | -68.38% | -38.23% |
| All-Time High | ₹348.45 (Dec 02, 2024) | ₹167.90 (Jan 11, 2016) |
| % from All-Time High | -68.38% | -41.88% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | -0.14% |
| Quarterly Earnings Growth | -0.56% | 0.23% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.02% |
| Operating Margin (TTM) | 0.07% | 0.07% |
| Return on Equity (TTM) | 0.14% | 0.10% |
| Debt to Equity (MRQ) | 0.00 | 196.55 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹80.33 | ₹39.09 |
| Cash per Share (MRQ) | ₹22.38 | ₹5.31 |
| Operating Cash Flow (TTM) | ₹161.60M | ₹203.15M |
| Levered Free Cash Flow (TTM) | ₹120.93M | ₹-153,328,752 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.20% |
| Last 12-Month Dividend | ₹0.00 | ₹1.20 |
Valuation & Enterprise Metrics Analysis: Par Drugs vs Bal Pharma
| Metric | PAR | BALPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 10.55 | 21.86 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | -2.84 |
| Price to Sales (TTM) | 1.40 | 0.54 |
| Price to Book (MRQ) | 1.43 | 2.53 |
| Market Capitalization | ||
| Market Capitalization | ₹1.41B | ₹1.65B |
| Enterprise Value | ₹1.17B | ₹3.34B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.16 | 1.10 |
| Enterprise to EBITDA | 5.98 | 11.31 |
| Risk & Other Metrics | ||
| Beta | -0.39 | 0.20 |
| Book Value per Share (MRQ) | ₹80.33 | ₹39.09 |
Financial Statements Comparison: Par Drugs vs Bal Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PAR | BALPHARMA |
|---|---|---|
| Revenue/Sales | ₹223.30M | ₹818.76M |
| Cost of Goods Sold | ₹97.77M | ₹439.73M |
| Gross Profit | ₹125.53M | ₹379.04M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹15.09M | ₹54.60M |
| EBITDA | ₹32.18M | ₹87.24M |
| Pre-Tax Income | ₹22.79M | ₹25.93M |
| Income Tax | ₹6.28M | ₹-28.25M |
| Net Income (Profit) | ₹16.51M | ₹54.19M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PAR | BALPHARMA |
|---|---|---|
| Cash & Equivalents | ₹275.77M | ₹17.52M |
| Total Current Assets | ₹548.61M | ₹2.35B |
| Total Current Liabilities | ₹165.69M | ₹2.20B |
| Long-Term Debt | ₹0 | ₹314.13M |
| Total Shareholders Equity | ₹989.75M | ₹774.04M |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹389.15M | ₹709.91M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PAR | BALPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PAR | BALPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 13,775 | 11,780 |
| Average Daily Volume (90 Day) | 8,786 | 16,006 |
| Shares Outstanding | 12.30M | 15.92M |
| Float Shares | 2.67M | 6.72M |
| % Held by Insiders | N/A | 0.65% |
| % Held by Institutions | N/A | 0.00% |
Dividend Analysis & Yield Comparison: Par Drugs vs Bal Pharma
| Metric | PAR | BALPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.20 |
| Last 12-Month Dividend Yield | N/A | 1.20% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹1.07 |
| 3-Year Avg Dividend Yield | N/A | 1.01% |
| 3-Year Total Dividends | ₹0.00 | ₹3.20 |
| Ex-Dividend Date | N/A | Sep 17, 2024 |
How to Actually Do This (Step by Step)
Don't overthink it. Here's exactly what to do:
Pick Another Stock to Compare
Use the search box above to find a similar company. Think competitors, companies in the same industry, or stocks you've heard about. Don't compare a tech startup to a utility company - that won't help much.
Look at the "Performance" Tab First
This shows you which stock has actually made more money for investors over time. If one is clearly winning year after year, that's worth paying attention to.
Check If the Price Makes Sense
Look at the "Valuation" tab. You want to see if you're paying a fair price for what you're getting. Sometimes the cheaper stock price isn't actually the better deal.
Trust Your Gut (But Verify with Data)
After looking at all the numbers, which company would you rather own a piece of? The data should support your intuition, not fight against it. If the numbers don't make sense to you, don't invest.
Ready to Make a Smarter Choice?
Use the search bar above to find a stock to compare with Par Drugs. In just a few minutes, you'll know whether you've found a great investment or if there's something better out there.
🙏 The Reality Check
Look, we're just showing you the numbers - we're not telling you what to buy. Stock prices go up and down, and past performance doesn't guarantee future results. You know your financial situation better than anyone else, so make decisions that make sense for you. If you're investing money you can't afford to lose, talk to a financial advisor first.